|
1
|
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
|
Nat Genet
|
1997
|
15.38
|
|
2
|
The somatic genomic landscape of glioblastoma.
|
Cell
|
2013
|
11.73
|
|
3
|
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
|
J Clin Oncol
|
1999
|
8.69
|
|
4
|
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
|
Cancer Res
|
1997
|
3.38
|
|
5
|
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.
|
Oncogene
|
2000
|
2.81
|
|
6
|
The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires.
|
Qual Life Res
|
1996
|
2.76
|
|
7
|
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
|
J Clin Oncol
|
2000
|
2.22
|
|
8
|
Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN.
|
Cancer Res
|
1999
|
1.95
|
|
9
|
Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling.
|
Cancer Res
|
1999
|
1.88
|
|
10
|
Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis.
|
Cancer Res
|
1999
|
1.66
|
|
11
|
Cognitive function as a predictor of survival in patients with recurrent malignant glioma.
|
J Clin Oncol
|
2000
|
1.66
|
|
12
|
Response and progression in recurrent malignant glioma.
|
Neuro Oncol
|
1999
|
1.57
|
|
13
|
Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis.
|
Cancer Res
|
1998
|
1.52
|
|
14
|
Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas.
|
Radiother Oncol
|
1991
|
1.47
|
|
15
|
Suppression of human glioma growth by adenovirus-mediated Rb gene transfer.
|
Neurology
|
1998
|
1.46
|
|
16
|
Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas.
|
Cancer Res
|
1981
|
1.44
|
|
17
|
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
|
Int J Radiat Oncol Biol Phys
|
1995
|
1.41
|
|
18
|
The autocrine loop of TGF-alpha/EGFR and brain tumors.
|
J Neurooncol
|
1997
|
1.40
|
|
19
|
The use of significant others as proxy raters of the quality of life of patients with brain cancer.
|
Med Care
|
1997
|
1.37
|
|
20
|
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
|
J Clin Oncol
|
2000
|
1.35
|
|
21
|
Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo.
|
Cancer Res
|
1999
|
1.28
|
|
22
|
Effect of disease burden on health-related quality of life in patients with malignant gliomas.
|
Neuro Oncol
|
2000
|
1.27
|
|
23
|
Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis.
|
Cancer Res
|
1996
|
1.21
|
|
24
|
Two tumor suppressive loci on chromosome 10 involved in human glioblastomas.
|
Genes Chromosomes Cancer
|
1995
|
1.21
|
|
25
|
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.
|
Eur J Cancer
|
2000
|
1.19
|
|
26
|
A reliability test of standard-based quantitative PCR: exogenous vs endogenous standards.
|
Mol Cell Probes
|
2000
|
1.18
|
|
27
|
Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo.
|
Nat Med
|
1998
|
1.18
|
|
28
|
Analysis of the functional role of chromosome 10 loss in human glioblastomas.
|
Cancer Res
|
1993
|
1.15
|
|
29
|
Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN.
|
Oncogene
|
2001
|
1.14
|
|
30
|
An intermediate filament-associated protein, p50, recognized by monoclonal antibodies.
|
J Cell Biol
|
1983
|
1.11
|
|
31
|
Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2.
|
Cancer Res
|
2001
|
1.07
|
|
32
|
Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis.
|
J Natl Cancer Inst
|
1997
|
1.07
|
|
33
|
Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma.
|
Oncogene
|
1997
|
1.06
|
|
34
|
Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture.
|
Cancer Res
|
1982
|
1.05
|
|
35
|
Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer.
|
Am J Clin Oncol
|
2001
|
1.03
|
|
36
|
Altered expression and distribution of heparan sulfate proteoglycans in human gliomas.
|
Cancer Res
|
1989
|
1.02
|
|
37
|
Clinical trial end points in malignant glioma: need for effective trial design strategy.
|
Semin Oncol
|
2000
|
1.01
|
|
38
|
Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma.
|
J Neurooncol
|
1997
|
0.99
|
|
39
|
Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors.
|
Ann Neurol
|
1993
|
0.99
|
|
40
|
Vimentin and glial fibrillary acidic protein in human brain tumors.
|
J Neurooncol
|
1985
|
0.99
|
|
41
|
The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.
|
Neurosurgery
|
1997
|
0.98
|
|
42
|
Expression of an altered epidermal growth factor receptor by human glioblastoma cells.
|
Cancer Res
|
1988
|
0.98
|
|
43
|
Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998.
|
Neuro Oncol
|
2001
|
0.98
|
|
44
|
Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity.
|
J Interferon Res
|
1990
|
0.98
|
|
45
|
Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway.
|
J Biol Chem
|
2001
|
0.97
|
|
46
|
Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells.
|
Clin Cancer Res
|
2001
|
0.97
|
|
47
|
Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development.
|
Clin Cancer Res
|
2000
|
0.95
|
|
48
|
Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas.
|
Cancer Res
|
1997
|
0.95
|
|
49
|
The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin).
|
J Neurooncol
|
1997
|
0.95
|
|
50
|
Imaging patterns of multifocal gliomas.
|
Eur J Radiol
|
1993
|
0.94
|
|
51
|
The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines.
|
Clin Cancer Res
|
2000
|
0.94
|
|
52
|
Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells.
|
Oncogene
|
1996
|
0.93
|
|
53
|
Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades.
|
Clin Exp Metastasis
|
2000
|
0.93
|
|
54
|
Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance.
|
Clin Cancer Res
|
1998
|
0.92
|
|
55
|
Functional and molecular analyses of 10q deletions in human gliomas.
|
Genes Chromosomes Cancer
|
1999
|
0.91
|
|
56
|
Central nervous system toxicity with high-dose Ara-C.
|
Neurology
|
1985
|
0.91
|
|
57
|
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
|
J Clin Oncol
|
1997
|
0.91
|
|
58
|
Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET.
|
Radiographics
|
1992
|
0.91
|
|
59
|
Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro.
|
Oncogene
|
1997
|
0.90
|
|
60
|
Diffuse bone marrow metastasis by glioblastoma: premortem diagnosis by peroxidase-antiperoxidase staining for glial fibrillary acidic protein.
|
Ann Neurol
|
1983
|
0.90
|
|
61
|
The treatment of anaplastic oligodendrogliomas and mixed gliomas.
|
Neurosurgery
|
1993
|
0.90
|
|
62
|
MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas.
|
AJNR Am J Neuroradiol
|
1995
|
0.89
|
|
63
|
Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
|
Clin Cancer Res
|
2001
|
0.88
|
|
64
|
Advances in chemotherapy for brain tumors.
|
Neurol Clin
|
1995
|
0.88
|
|
65
|
Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling.
|
Histol Histopathol
|
2000
|
0.88
|
|
66
|
Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
|
Oncogene
|
1996
|
0.87
|
|
67
|
Prognostic significance of p53 immunoreactivity in patients with glioma.
|
Clin Cancer Res
|
1995
|
0.87
|
|
68
|
A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
|
Int J Radiat Oncol Biol Phys
|
1999
|
0.87
|
|
69
|
All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma.
|
J Neurooncol
|
1997
|
0.86
|
|
70
|
Delivery of cell cycle genes to block astrocytoma growth.
|
J Neurooncol
|
2001
|
0.85
|
|
71
|
Irinotecan: promising activity in the treatment of malignant glioma.
|
Oncology (Williston Park)
|
2003
|
0.85
|
|
72
|
Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF.
|
Br J Cancer
|
2001
|
0.85
|
|
73
|
'Glioblastoma'. Induction of a reproducible autochonous tumor in rats with murine sarcoma virus.
|
Neurology
|
1976
|
0.84
|
|
74
|
Correlation between dynamic MRI and outcome in patients with malignant gliomas.
|
Neurology
|
1998
|
0.84
|
|
75
|
Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis.
|
Neuro Oncol
|
2001
|
0.84
|
|
76
|
Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses.
|
Exp Cell Res
|
1999
|
0.84
|
|
77
|
Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells.
|
J Cell Biochem
|
1986
|
0.83
|
|
78
|
Two primitive neuroectodermal tumor cell lines require an activated insulin-like growth factor I receptor for growth in vitro.
|
Neurosurgery
|
1996
|
0.83
|
|
79
|
Adenovirus-mediated p53 gene therapy for human gliomas.
|
Neurosurgery
|
1999
|
0.83
|
|
80
|
Treatment of recurrent gliomas with eflornithine.
|
J Natl Cancer Inst
|
1992
|
0.83
|
|
81
|
Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.
|
Neuro Oncol
|
2000
|
0.82
|
|
82
|
Growth regulatory activities of endothelial extracellular matrix: mediation by transforming growth factor-beta.
|
Exp Cell Res
|
1990
|
0.82
|
|
83
|
Targeting in gene therapy for gliomas.
|
Arch Neurol
|
1999
|
0.81
|
|
84
|
Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors.
|
Cancer
|
1984
|
0.81
|
|
85
|
Transforming growth factor-alpha antisense vectors can inhibit glioma cell growth.
|
J Neurooncol
|
1999
|
0.81
|
|
86
|
Multifocal cerebral gliomas associated with secondary malignancies.
|
Lancet
|
1992
|
0.80
|
|
87
|
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
|
J Neurooncol
|
2016
|
0.80
|
|
88
|
A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes.
|
Int J Oncol
|
1998
|
0.79
|
|
89
|
Gamma-ray mutagen sensitivity and survival in patients with glioma.
|
Clin Cancer Res
|
1998
|
0.79
|
|
90
|
Altered actin cytoskeleton and inhibition of matrix metalloproteinase expression by vanadate and phenylarsine oxide, inhibitors of phosphotyrosine phosphatases: modulation of migration and invasion of human malignant glioma cells.
|
Mol Carcinog
|
1999
|
0.79
|
|
91
|
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
|
Neurosurgery
|
1996
|
0.79
|
|
92
|
Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells.
|
Int J Oncol
|
2001
|
0.78
|
|
93
|
Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.
|
J Neurosurg
|
1998
|
0.78
|
|
94
|
The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies.
|
Neurology
|
1998
|
0.78
|
|
95
|
Resolution of recurrent malignant ganglioglioma after treatment with cis-retinoic acid.
|
J Neurooncol
|
1996
|
0.78
|
|
96
|
Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy.
|
Int J Oncol
|
1998
|
0.78
|
|
97
|
Inhibition of epidermal growth factor receptor activity by retinoic acid in glioma cells.
|
J Cell Biochem
|
1990
|
0.78
|
|
98
|
Phase II trial of mitogauzone in malignant primary brain tumors.
|
Cancer Treat Rep
|
1985
|
0.78
|
|
99
|
Factors influencing the mode of delivery and associated pregnancy outcomes for twins: a retrospective cohort study in a public hospital.
|
Hong Kong Med J
|
2012
|
0.78
|
|
100
|
Delayed neurotoxicity of intraventricular interleukin-2: a case report.
|
J Neurooncol
|
1993
|
0.77
|
|
101
|
Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma.
|
J Natl Cancer Inst
|
1988
|
0.77
|
|
102
|
Glioblastoma multiforme: treatment with radiation and triiodothyronine.
|
Int J Radiat Oncol Biol Phys
|
1977
|
0.77
|
|
103
|
Intracarotid VP-16 in malignant brain tumors.
|
J Neurooncol
|
1987
|
0.77
|
|
104
|
Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis.
|
Int J Mol Med
|
1999
|
0.77
|
|
105
|
Anguidine potentiates cis-platinum in human brain tumor cells.
|
J Neurooncol
|
1986
|
0.77
|
|
106
|
The modulation of astrocytic differentiation in cells derived from a medulloblastoma surgical specimen.
|
J Neurooncol
|
1989
|
0.77
|
|
107
|
New drugs and new delivery techniques.
|
Prog Exp Tumor Res
|
1985
|
0.76
|
|
108
|
Identification of a novel gene product, RIG, that is down-regulated in human glioblastoma.
|
Oncogene
|
1997
|
0.76
|
|
109
|
High dose Ara-C related leukoencephalopathy.
|
J Neurooncol
|
1986
|
0.76
|
|
110
|
Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors.
|
Cancer Drug Deliv
|
1986
|
0.76
|
|
111
|
Suppression of transformed phenotype and tumorigenicity after transfer of chromosome 4 into U251 human glioma cells.
|
Genes Chromosomes Cancer
|
1997
|
0.76
|
|
112
|
Potentials and limitations of adenovirus-p53 gene therapy for brain tumors.
|
J Korean Med Sci
|
2000
|
0.76
|
|
113
|
Phase-I trial of intracarotid BCNU and cisplatin in patients with malignant intracerebral tumors.
|
Cancer Drug Deliv
|
1984
|
0.76
|
|
114
|
BUdR radiosensitization in anaplastic astrocytoma.
|
Int J Radiat Oncol Biol Phys
|
1999
|
0.75
|
|
115
|
Modulation of serine proteinases and metalloproteinases during morphogenic glial-endothelial interactions.
|
J Neurochem
|
1996
|
0.75
|
|
116
|
Assessing response to chemotherapy in malignant glioma: the role of steroids.
|
Neurology
|
1998
|
0.75
|
|
117
|
In vitro effects of ACNU, BCNU, CDDP, and bleomycin on human glioma cells.
|
Neurol Med Chir (Tokyo)
|
1988
|
0.75
|
|
118
|
Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee.
|
Int J Radiat Oncol Biol Phys
|
2001
|
0.75
|
|
119
|
A frequent polymorphism in exon 1 of the p16/CDKN2 gene.
|
Mol Cell Probes
|
1995
|
0.75
|
|
120
|
A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
|
J Neurooncol
|
1984
|
0.75
|
|
121
|
Regional nerve injury after intra-arterial chemotherapy.
|
Neurology
|
1987
|
0.75
|
|
122
|
Radiation Therapy Oncology Group. Research Plan 2002-2006. Brain Tumor Committee.
|
Int J Radiat Oncol Biol Phys
|
2001
|
0.75
|
|
123
|
Meningeal gliomatosis: a review of twelve cases.
|
Trans Am Neurol Assoc
|
1979
|
0.75
|
|
124
|
A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas.
|
J Neurooncol
|
1983
|
0.75
|
|
125
|
Differentially expressed gene products in glioblastoma cells suppressed for tumorigenicity.
|
J Neurovirol
|
1998
|
0.75
|
|
126
|
Molecular genetics and tumour suppressor genes in gliomas.
|
Baillieres Clin Neurol
|
1996
|
0.75
|
|
127
|
Planned conservative management of placenta accreta - experience of a regional general hospital.
|
J Matern Fetal Neonatal Med
|
2013
|
0.75
|
|
128
|
Altered expression of glycosaminoglycans in metastatic 13762NF rat mamma adenocarcinoma cells.
|
Biochemistry
|
1987
|
0.75
|
|
129
|
DNA synthesis in fast- and slow-growing C57BL ascites tumors.
|
Cancer Res
|
1974
|
0.75
|
|
130
|
Brain and meningeal biopsy in patients with acquired immunodeficiency syndrome.
|
Tex Med
|
1986
|
0.75
|
|
131
|
Neurotoxicity of high-dose Ara-C and intracarotid chemotherapy.
|
Prog Exp Tumor Res
|
1985
|
0.75
|